MedTrace Logo

Validation of an Electronic Remote Toxicity Management System in Cancer Patients

NCT04915274 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2022-01-18

No results posted yet for this study

Summary

To assess the psychometric properties (validity, reliability and responsiveness) of the QuestOnco tool, an electronic Remote Toxicity Management System, in adult cancer patients receiving an active anti-cancer treatment.

Conditions

Interventions

OTHER

uses of an application

Patients will be advised that they can still use their QuestOnco handset if they are hospitalized only for a treatment-related toxicity.

Sponsors & Collaborators

  • Centre Hospitalier Régional Metz-Thionville

    lead OTHER

Principal Investigators

  • Raffaele LONGO · CHR METZ THIONVILLE

  • Véronique NOIREZ · CHR METZ THIONVILLE

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-18
Primary Completion
2022-01-12
Completion
2022-01-12

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04915274 on ClinicalTrials.gov